Mass General Brigham has spun out AIwithCare, a company commercializing RECTIFIER, an AI tool that automates and enhances clinical trial patient screening using EHR data.
Key Details
- 1RECTIFIER, developed at Mass General Brigham, leverages Retrieval-Augmented Generation (RAG) AI to assess patient eligibility for clinical trials via EHRs, including unstructured notes and reports.
- 2In a 2024 NEJM AI study, RECTIFIER outperformed manual screening methods for a heart failure trial at lower cost.
- 3A randomized-controlled trial involving nearly 4,500 patients showed RECTIFIER doubled the enrollment rate compared to manual screening, with no differences across demographic groups.
- 4RECTIFIER is in use for over 20 clinical and research applications including oncology, neurology, pathology, and cardiology.
- 5Mass General Brigham Innovation facilitated the spinout, aiming for broader deployment across health systems via the AIwithCare platform.
- 6RECTIFIER is also being applied to population health and referral triage, showing >94% accuracy in select use cases.
Why It Matters
Accelerating and automating patient screening for trials using AI—including extraction from imaging reports—may boost trial efficiency, reduce research staff workload, and expand equitable patient access to advanced therapies. This reflects a broader trend of integrating AI into real-world clinical informatics, directly impacting radiology and multi-disciplinary care coordination.
Source
EurekAlert
Related News
•EurekAlert
USC Unveils Joint Biomedical Engineering Department Bridging Medicine, Engineering, and Imaging
USC's medical and engineering schools launch a joint biomedical engineering department to accelerate interdisciplinary research and innovation, including imaging and AI.
•EurekAlert
AI Software Matches Invasive Gold Standard in Coronary Flow Assessment
AI-based FFRangio software performs comparably to invasive pressure wire methods for evaluating coronary artery disease in a major international clinical trial.
•EurekAlert
Molecular Test BiliSeq Greatly Improves Bile Duct Cancer Detection
The BiliSeq molecular test developed at UPMC doubled detection sensitivity for bile duct cancer compared to standard pathology.